{"id":"oral-testosterone-undecanoate","safety":{"commonSideEffects":[{"rate":null,"effect":"Polycythemia"},{"rate":null,"effect":"Acne"},{"rate":null,"effect":"Gynecomastia"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Testosterone undecanoate is an esterified form of testosterone designed for oral absorption. It is absorbed through the lymphatic system via the intestinal tract, bypassing first-pass hepatic metabolism, and is then hydrolyzed to release free testosterone. This allows for sustained restoration of testosterone levels in men with testosterone deficiency.","oneSentence":"Oral testosterone undecanoate is a testosterone replacement therapy that restores physiological testosterone levels in hypogonadal men.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:52.199Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Testosterone replacement therapy in adult males with hypogonadism"}]},"trialDetails":[{"nctId":"NCT05081193","phase":"PHASE2","title":"Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-03-07","conditions":"Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":15},{"nctId":"NCT06393634","phase":"EARLY_PHASE1","title":"Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration","status":"COMPLETED","sponsor":"Sports Medicine Research and Testing Laboratory","startDate":"2024-11-27","conditions":"Healthy","enrollment":14},{"nctId":"NCT06082817","phase":"PHASE2","title":"An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD","status":"NOT_YET_RECRUITING","sponsor":"San Diego Sexual Medicine","startDate":"2025-01-01","conditions":"Hypoactive Sexual Desire Disorder","enrollment":30},{"nctId":"NCT04685993","phase":"PHASE2","title":"A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2020-11-11","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":25},{"nctId":"NCT04467697","phase":"PHASE3","title":"Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men","status":"COMPLETED","sponsor":"Marius Pharmaceuticals","startDate":"2018-09-18","conditions":"Hypogonadism, Male","enrollment":155},{"nctId":"NCT06312761","phase":"PHASE1, PHASE2","title":"Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2024-06-01","conditions":"Hypogonadism, Male","enrollment":10},{"nctId":"NCT04134091","phase":"PHASE2","title":"The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2019-08-27","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":56},{"nctId":"NCT04983940","phase":"PHASE4","title":"Patient Satisfaction After Switching to Oral Testosterone Undecanoate","status":"COMPLETED","sponsor":"University of Miami","startDate":"2021-06-18","conditions":"Testosterone Deficiency","enrollment":41},{"nctId":"NCT02248701","phase":"PHASE2","title":"Testosterone Plus Finasteride Treatment After Spinal Cord Injury","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2017-04-27","conditions":"Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System","enrollment":33},{"nctId":"NCT03198728","phase":"PHASE3","title":"Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men","status":"COMPLETED","sponsor":"Marius Pharmaceuticals","startDate":"2017-07-05","conditions":"Hypogonadism, Male","enrollment":314},{"nctId":"NCT01699178","phase":"PHASE3","title":"Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2012-08","conditions":"Male Hypogonadism","enrollment":182},{"nctId":"NCT00695110","phase":"PHASE2","title":"Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2008-06","conditions":"Hypogonadism","enrollment":29},{"nctId":"NCT03868059","phase":"PHASE3","title":"Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2018-04-30","conditions":"Hypogonadism, Male","enrollment":138},{"nctId":"NCT00911586","phase":"PHASE2","title":"Pharmacokinetic Study to Determine Time to Steady-state","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2009-07","conditions":"Male Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism","enrollment":15},{"nctId":"NCT00924612","phase":"PHASE2","title":"Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2009-07","conditions":"Male Hypogonadism","enrollment":16},{"nctId":"NCT04545450","phase":"PHASE3","title":"Effects of Testosterone Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolism in Transmen","status":"COMPLETED","sponsor":"Unita Complessa di Ostetricia e Ginecologia","startDate":"2008-11-04","conditions":"Transgenderism, Hypogonadism","enrollment":16},{"nctId":"NCT02966652","phase":"PHASE1","title":"Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2016-11-03","conditions":"Male Hypogonadism","enrollment":25},{"nctId":"NCT03242590","phase":"PHASE3","title":"Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2016-12","conditions":"Hypogonadism, Male","enrollment":95},{"nctId":"NCT03242408","phase":"PHASE3","title":"Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2017-01","conditions":"Hypogonadism, Male","enrollment":100},{"nctId":"NCT00239590","phase":"PHASE2","title":"Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2001-06","conditions":"Coronary Heart Disease","enrollment":28},{"nctId":"NCT03973840","phase":"PHASE1","title":"Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2018-07-15","conditions":"Hypogonadism, Male","enrollment":13},{"nctId":"NCT02697188","phase":"PHASE2","title":"Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2007-11","conditions":"Hypogonadism","enrollment":12},{"nctId":"NCT01403116","phase":"PHASE3","title":"Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2011-07","conditions":"Male Hypogonadism","enrollment":325},{"nctId":"NCT02921386","phase":"PHASE2","title":"The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2016-10","conditions":"Hypogonadism","enrollment":18},{"nctId":"NCT02670343","phase":"PHASE1, PHASE2","title":"Phlebotomy Study of Testosterone Undecanoate","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2016-01","conditions":"Hypogonadism","enrollment":8},{"nctId":"NCT02722278","phase":"PHASE3","title":"A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2016-03","conditions":"Hypogonadism","enrollment":222},{"nctId":"NCT01765179","phase":"PHASE3","title":"Safety and Efficacy Trial of Testosterone Undecanoate","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2013-01","conditions":"Male Hypogonadism","enrollment":144},{"nctId":"NCT02081300","phase":"PHASE3","title":"Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2014-02","conditions":"Male Hypogonadism","enrollment":315},{"nctId":"NCT02222558","phase":"PHASE2","title":"Oral Testosterone for the Treatment of Hypogonadism in Males","status":"COMPLETED","sponsor":"TesoRx Pharma, LLC","startDate":"2014-09","conditions":"Hypogonadism","enrollment":25},{"nctId":"NCT01717768","phase":"PHASE2","title":"Oral Testosterone for the Treatment of Hypogonadism","status":"COMPLETED","sponsor":"TesoRx Pharma, LLC","startDate":"2012-10","conditions":"Hypogonadism","enrollment":130},{"nctId":"NCT00434824","phase":"PHASE2","title":"Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11","conditions":"Hypogonadism, Androgens","enrollment":322},{"nctId":"NCT01516554","phase":"PHASE2","title":"Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients","status":"TERMINATED","sponsor":"Health Sciences Centre, Winnipeg, Manitoba","startDate":"2012-02","conditions":"Multiple Sclerosis, Fatigue","enrollment":3},{"nctId":"NCT01724658","phase":"PHASE2","title":"Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2012-06","conditions":"Female Sexual Dysfunction","enrollment":70},{"nctId":"NCT00842751","phase":"PHASE2","title":"Oral T7 Oral Testosterone in Man","status":"COMPLETED","sponsor":"University of Washington","startDate":"2009-07","conditions":"Healthy Males, Male Contraceptive","enrollment":11},{"nctId":"NCT00230984","phase":"PHASE3","title":"IRAD2 : Patients With Respiratory Failure at Home","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2003-04","conditions":"Chronic Respiratory Failure, Nutritional Depletion","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":120,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kyzatrex","testosterone undecanoate","Oral TU"],"phase":"phase_3","status":"active","brandName":"Oral Testosterone Undecanoate","genericName":"Oral Testosterone Undecanoate","companyName":"Clarus Therapeutics, Inc.","companyId":"clarus-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral testosterone undecanoate is a testosterone replacement therapy that restores physiological testosterone levels in hypogonadal men. Used for Testosterone replacement therapy in adult males with hypogonadism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}